BioNote KRX:377740KOSPI
바이오노트 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q2 2026, BioNote reported revenue of ₩36.4bn, up 12.2% year on year, and operating profit of ₩8.5bn. BioNote (바이오노트) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Revenue & profit growth Op. margin 20%+ Screener
BioNote quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩36.4bn | +12.2% | ₩8.5bn margin 23.3% | ₩9.1bn |
| Q1 2026 | ₩32.6bn | +14.5% | ₩6.3bn margin 19.5% | ₩41.3bn |
| Q4 2025 derived | ₩28.0bn | +13.0% | ₩840m margin 3.0% | −₩194bn |
| Q3 2025 | ₩29.5bn | +11.5% | ₩4.8bn margin 16.3% | ₩17.9bn |
| Q2 2025 | ₩32.4bn | +23.3% | ₩6.3bn margin 19.6% | ₩84.5bn |
| Q1 2025 | ₩28.4bn | +12.4% | ₩4.7bn margin 16.5% | ₩4.0bn |
| Q4 2024 derived | ₩24.7bn | +13.7% | ₩2.5bn margin 10.3% | – |
| Q3 2024 | ₩26.4bn | +21.7% | ₩3.5bn margin 13.4% | – |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
BioNote top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest BioNote news Korean headlines
No articles yet.